Author is bullish on ImmunityBio, arguing its Anktiva cancer treatment is being blocked by the FDA while already approved in Saudi Arabia, and that approval would save lives.
IBRX β LONG The author argues ImmunityBio's Anktiva, a superagonist fusion complex that activates Natural Killer cells and memory T cells, has shown long-term success but is being blocked by the FDA despite over a million pages of data. Saudi Arabia has already approved Anktiva, and the author implies US approval would be a major catalyst. The author frames this as a life-saving treatment that could force the FDA's hand.
This data is sitting in the hands of the FDA, but unfortunately our FDA has not reviewed it. Saudi Arabia on the other hand, has chosen longevity science and health span as a measure of GDP and has approved Anktiva for use in the country.
This Reddit post, published January 20, 2026, features u/TraditionPrimary6781 discussing IBRX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/TraditionPrimary6781 · Tickers: IBRX